Cationic Peptides for Antibacterial Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a pressing need for effective treatments against drug-resistant bacterial infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, as existing antibiotics have limited efficacy due to widespread resistance.
Innovation Solution
Development of peptides composed substantially of basic amino acids, such as arginine or lysine, which are highly bactericidal and can be used as antibacterial agents to treat bacterial infections, including those caused by Staphylococcal and Pseudomonad strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then treatment efficacy is initially good, but bacterial resistance develops leading to treatment failure
Solution Approach 1:
The patent changes the fundamental parameter of antimicrobial agents from conventional antibiotics to cationic peptides with specific amino acid compositions. The peptides are characterized by having a minimum of 30% basic amino acids (arginine, lysine, or histidine) and a maximum of 70% non-basic amino acids, creating a novel chemical structure that bacteria have not evolved resistance against
Solution Approach 2:
The patent exploits the harmful cationic charge of the peptides, which normally causes cell membrane disruption and cell death, as the key mechanism for effective antibacterial action. The positive charge facilitates interaction with negatively charged bacterial membranes, creating pores that lead to cell lysis - a mechanism that bacteria cannot resist
2Reliability
If cationic peptides are used as antimicrobial agents, then bacterial resistance is minimized, but peptide stability and delivery challenges arise
Solution Approach 1:
The patent designs peptides that can be administered through multiple routes (oral, inhalation, intravenous, intraperitoneal, intramuscular, subcutaneous, topical, ophthalmic, otic, rectal, vaginal) making them universally applicable for treating various bacterial infections including MRSA, Pseudomonas aeruginosa, and other Gram-positive and Gram-negative bacteria
Solution Approach 2:
The patent optimizes peptide parameters including length (5-50 amino acids), basic amino acid content (30-70%), and specific sequence compositions to enhance stability and efficacy while maintaining compatibility with different delivery routes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides demonstrate significant antibacterial activity against a range of bacterial strains, including resistant strains, offering a potential new therapeutic approach for treating bacterial infections effectively.
Implementation Method 1
Many antimicrobial peptides are characterised by cationic properties that facilitate interactions with the negatively charged phospholipids of the microbial membrane which then lead to microbial lysis and death following subsequent membrane permeabilisation
Implementation Method 2
The amphiphilic nature of these molecules may also facilitate the insertion of the hydrophobic residue into the lipid bilayer by electrostatic attraction while the polar residues project into and above the membrane
Data Source
AI summary
The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino acids in the amino sequence of said peptide are the same, for use as antibacterial agents.